Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS
Recruiting now
Conditions studied: Schizophrenia, Negative Symptoms in Schizophrenia, Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis), Cognitive Deficit
In brief
This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample. This will be done by comparing results obtained from the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale with results obtained from the Positive and Negative Symptoms Scale, the Montgomery Asberg Depression Rating Scale, and the Montreal Cognitive Assessment test.
Key facts
- Study ID
- NCT06278532
- Run by
- Lithuanian University of Health Sciences
- People needed
- 200
- Starts
- 2023-12-11
- Expected to finish
- 2026-12-11
- Last updated by the study team
- 2024-02-26
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- age 18 - 65 years old;
- Diagnosis of F20, F25 or F21 according to ICD-10;
- Signed informed consent form.
You may not qualify if…
- Age younger than 18 or older than 65 years old;
- Did not sign the informed consent form;
- Legally inactive person
- Patients with a comorbid or primary diagnosis of mental retardation according to ICD-10 (F70 - F79);
- Patients with a comorbid or primary diagnosis of mental and behavioural disorders due to psychoactive substance use (F10 - F19)
- Patients with a comorbid of primary diagnosis of organic, including symptomatic, mental disorders (F00 - F09)
Where it is running
- Lithuanian University of Health Sciences Hospital Kaunas Clinics — Kaunas, Lithuania (enrolling)
- Jonas Montvidas — Kaunas, Lithuania (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.